Eyeworld

by Title ASCRS NEWS Heading Name title Contact Name: email 22 | EYEWORLD | SUMMER 2026 to be able to survive and thrive in the financial climate affecting practices. Dr. Miller has been involved with ASCRS for many years. He first started attending the ASCRS Annual Meeting decades ago when it took place at the Century Plaza Hotel in Los Angeles, California. As a third-year resident attend- ing his first meeting, Dr. Miller noted the impact of being in the same room as all the "big shots" in ophthalmology, getting to hear their thoughts, and talking with them. "I was inspired by the people I met, and everything was super innovative. I could take things home and immediately start using them," he said. "Everything was actionable, and that makes an impact on the lives of the patients that we are treating." Dr. Miller called the ASCRS Annual Meeting atmo- sphere "invigorating," making it a group that he wanted to be a part of. He recalled stepping up to the podium to present a paper for the first time, the "beginning of my ASCRS career." Dr. Miller added that for young ophthalmologists, ASCRS provides a platform for showing their research, innovative ideas, and surgical techniques, and they get an audience they can speak to and get immediate feedback from because people in the room are very knowledgeable. "It's a stimulating environment," he said. "ASCRS encourag- es people to come and present—it's not exclusive. Everyone has an opportunity to get their foot in the door, and others in the Society are very encouraging; it's a group effort." Throughout his career, Dr. Miller has been involved with ASCRS on the Cataract Clinical Committee (includ- ing as chair), Skills Transfer Sub-Committee, and with EyeWorld, where he led the Complicated Cataract Cases column for several years. He continued to work within the Society and on programming and was asked to join in a leadership role. During his presidency, ASCRS will continue in the ef- forts it's well known for, such as with EyeSustain and Clin- ical Committee white papers. "That will never stop. We'll always be innovating there," Dr. Miller said. "We'll also be looking out for new problems, burdensome government regulations, FDA issues, innovative opportunities, etc." "Any time something comes up, we're going to con- tinue to address it as a Society," he said, again stressing the importance of the Clinical Committees. "We want to en- courage people to get involved and get on the committees," he said. "If you're young, get on the YES Clinical Commit- tee, and you can work your way up." IMPORTANT PRODUCT INFORMATION ARGOS ® Optical Biometer Caution: Federal (USA) law restricts this device to the sale by or on the order of a physician. Indications: ARGOS ® is a non-invasive, non-contact biometer based on swept-source optical coherence tomography (SS-OCT). The device is intended to acquire ocular measurements as well as perform calculations to determine the appropriate intraocular lens (IOL) power and type for implantation during intraocular lens placement. Intended Use: The Reference Image functionality is intended for use as a preoperative and postoperative image capture tool. It is intended for use by ophthalmologists, physicians, and other eye- care professionals and may only be used under the supervision of a physician. Warnings and Precautions: • Only properly trained personnel with experience may operate the device and control software and interpret the results. • Factors that influence the measurement of patient's eyes are listed in the User Manual (Table 1): pseudophakic eye, wearing contact lenses, fixation problem, cornea opacity, non-intact cornea, refractive surgery, blood in the vitreous humor, retinal detachment, keratoconus, asteroid hyalosis, ambient light in the room, and deformation of the corneal shape. Please consider the guidance provided in Table 1 when you encounter these factors. • Optical Radiation - This device is equipped with a Class 1 laser light source. ATTENTION: Refer to the ARGOS ® User Manual for a complete description of proper use and maintenance, optical and technical specifications, as well as a complete list of warnings and precautions. © 2026 Alcon Inc. US-ARB-2600001 continued from page 20

• Blank Page
• Blank Page (1)